Merck & Co., Inc. (ETR:6MK)
71.40
-0.30 (-0.42%)
Aug 15, 2025, 5:35 PM CET
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
€732,014
Profits / Employee
€188,780
Market Cap
179.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Merck KGaA | 59,020 |
Bayer Aktiengesellschaft | 91,864 |
Fresenius SE & Co. KGaA | 176,486 |
Fresenius Medical Care AG | 111,513 |
Sartorius Aktiengesellschaft | 13,528 |
Fielmann Group AG | 24,363 |
Carl Zeiss Meditec AG | 5,730 |
Merck & Co. News
- 3 days ago - 10 Undervalued Dividend Growth Stocks: August 2025 - Seeking Alpha
- 3 days ago - Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer - Seeking Alpha
- 3 days ago - KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery - Wallstreet:Online
- 3 days ago - KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery - Business Wire
- 4 days ago - IO Biotech says cancer vaccine with Merck’s Keytruda outperformed in late-stage study - Seeking Alpha
- 8 days ago - August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys - Seeking Alpha
- 9 days ago - Stock Picks From Seeking Alpha's July 2025 New Analysts - Seeking Alpha
- 10 days ago - Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Wallstreet:Online